利空突袭！减肥药巨头，股价暴跌

Core Viewpoint - Novo Nordisk's stock price has significantly dropped due to a bleak earnings outlook for 2026, which is substantially below market expectations [2][6]. Group 1: Earnings Guidance - The company announced that its 2026 earnings forecast indicates a sales and operating profit decline of 5% to 13% at constant exchange rates, which is far worse than analysts' expectations [6]. - CEO Mike Doustdar highlighted that the company will face pricing pressures in an increasingly competitive market, particularly affecting its best-selling weight loss drugs [6][9]. - In 2025, Novo Nordisk's sales grew by 10% and operating profit by 6%, with Q4 net sales reaching 79.1 billion Danish Krone (approximately 12.5 billion USD), slightly above analyst expectations [7]. Group 2: Market Dynamics - The company is expected to face significant pricing pressure in the U.S. market, which is its largest, while other markets may see growth [7]. - The loss of exclusivity for Wegovy and Ozempic in Canada, Brazil, and China in 2026 adds to the competitive challenges [9]. - Novo Nordisk plans to launch a higher dosage version of Wegovy in more markets in 2026, aiming to boost sales despite the competitive landscape [8]. Group 3: Competitive Landscape - Novo Nordisk is under pressure from competitors like Eli Lilly, which has introduced weight loss drugs that outperform its products [10]. - The company's stock has dropped over 40% in 2025 due to multiple earnings guidance downgrades and management changes [9]. - Analysts are closely monitoring Novo Nordisk's ability to leverage its first-mover advantage in the oral GLP-1 weight loss therapy market [9].